Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antagomir-323a
- Development stage
- Preclinical
- Lead developer
- RiboBio
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Antagomir-323a is a cholesterol-conjugated, chemically modified single-stranded antisense oligonucleotide that functions as a microRNA inhibitor targeting microRNA-323a-3p (miR-323a-3p). By binding to miR-323a-3p, it prevents the microRNA from suppressing its target genes, such as tissue inhibitor of metalloproteinase 3 (TIMP3). In preclinical studies, antagomir-323a has been shown to alleviate pressure overload-induced cardiac fibrosis, improve cardiac function, and inhibit the expression of transforming factor-beta (TGF-β). It is widely used as a research tool to study the regulatory roles of miR-323a-3p in various pathological conditions.
- Other names
- miR-323a-3p inhibitormiR323a-3p inhibitormiR 323a-3p inhibitor
Beyond the preview
Go deeper on antagomir-323a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antagomir-323a.